News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
857,576 Results
Type
Article (87200)
Company Profile (705)
Press Release (769647)
Multimedia
Podcasts (162)
Webinars (24)
Section
Business (232959)
Career Advice (4136)
Deals (39780)
Drug Delivery (133)
Drug Development (91192)
Employer Resources (200)
FDA (18244)
Job Trends (17384)
News (397166)
Policy (39890)
Tag
Academia (3003)
Academic (2)
Accelerated approval (17)
Adcomms (33)
Allergies (117)
Alliances (56979)
ALS (134)
Alzheimer's disease (1637)
Antibody-drug conjugate (ADC) (204)
Approvals (18229)
Artificial intelligence (450)
Autoimmune disease (43)
Automation (23)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (145)
Biotechnology (483)
Bladder cancer (116)
Brain cancer (46)
Breast cancer (431)
Cancer (3478)
Cardiovascular disease (303)
Career advice (3550)
Career pathing (36)
CAR-T (225)
CDC (45)
Cell therapy (620)
Cervical cancer (29)
Clinical research (74849)
Collaboration (1257)
Company closure (4)
Compensation (845)
Complete response letters (48)
COVID-19 (2939)
CRISPR (75)
C-suite (481)
Cystic fibrosis (128)
Data (3655)
Decentralized trials (2)
Denatured (58)
Depression (92)
Diabetes (409)
Diagnostics (7035)
Digital health (28)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (213)
Drug pricing (168)
Drug shortages (36)
Duchenne muscular dystrophy (179)
Earnings (98617)
Editorial (52)
Employer branding (25)
Employer resources (169)
Events (132326)
Executive appointments (947)
FDA (20433)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1114)
Gene editing (161)
Generative AI (44)
Gene therapy (489)
GLP-1 (983)
Government (5340)
Grass and pollen (7)
Guidances (330)
Healthcare (20934)
HIV (48)
Huntington's disease (32)
IgA nephropathy (52)
Immunology and inflammation (209)
Immuno-oncology (17)
Indications (45)
Infectious disease (3154)
Inflammatory bowel disease (177)
Inflation Reduction Act (13)
Influenza (86)
Intellectual property (156)
Interviews (814)
IPO (17920)
IRA (59)
Job creations (5195)
Job search strategy (2863)
Kidney cancer (15)
Labor market (67)
Layoffs (619)
Leadership (30)
Legal (10143)
Liver cancer (88)
Longevity (12)
Lung cancer (501)
Lymphoma (250)
Machine learning (22)
Management (65)
Manufacturing (545)
MASH (115)
Medical device (14814)
Medtech (14831)
Mergers & acquisitions (22666)
Metabolic disorders (1049)
Multiple sclerosis (115)
NASH (23)
Neurodegenerative disease (177)
Neuropsychiatric disorders (49)
Neuroscience (2509)
NextGen: Class of 2025 (7687)
Non-profit (5094)
Now hiring (54)
Obesity (528)
Opinion (302)
Ovarian cancer (112)
Pain (149)
Pancreatic cancer (142)
Parkinson's disease (212)
Partnered (27)
Patents (377)
Patient recruitment (251)
Peanut (56)
People (66016)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (23075)
Phase II (32500)
Phase III (24468)
Pipeline (2409)
Policy (277)
Postmarket research (3554)
Preclinical (10419)
Press Release (72)
Prostate cancer (169)
Psychedelics (49)
Radiopharmaceuticals (281)
Rare diseases (589)
Real estate (7409)
Recruiting (76)
Regulatory (27630)
Reports (64)
Research institute (2672)
Resumes & cover letters (650)
Rett syndrome (11)
RNA editing (15)
RSV (63)
Schizophrenia (116)
Series A (183)
Series B (137)
Service/supplier (30)
Sickle cell disease (75)
Special edition (24)
Spinal muscular atrophy (168)
Sponsored (39)
Startups (4314)
State (2)
Stomach cancer (17)
Supply chain (90)
Tariffs (81)
The Weekly (102)
Vaccines (1001)
Venture capital (63)
Weight loss (363)
Women's health (56)
Worklife (21)
Date
Today (124)
Last 7 days (759)
Last 30 days (2614)
Last 365 days (34108)
2025 (23115)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (77)
Alaska (7)
Arizona (292)
Arkansas (14)
Asia (50767)
Australia (8915)
California (8798)
Canada (2671)
China (822)
Colorado (371)
Connecticut (389)
Delaware (237)
Europe (116572)
Florida (1300)
Georgia (302)
Hawaii (3)
Idaho (67)
Illinois (783)
India (45)
Indiana (425)
Iowa (19)
Japan (265)
Kansas (121)
Kentucky (35)
Louisiana (20)
Maine (75)
Maryland (1203)
Massachusetts (6644)
Michigan (294)
Minnesota (537)
Mississippi (4)
Missouri (113)
Montana (32)
Nebraska (26)
Nevada (99)
New Hampshire (75)
New Jersey (2424)
New Mexico (31)
New York (2402)
North Carolina (1343)
North Dakota (10)
Northern California (3913)
Ohio (279)
Oklahoma (18)
Oregon (49)
Pennsylvania (1846)
Puerto Rico (18)
Rhode Island (44)
South America (1654)
South Carolina (45)
South Dakota (1)
Southern California (3326)
Tennessee (142)
Texas (1367)
United States (32703)
Utah (263)
Virginia (237)
Washington D.C. (82)
Washington State (756)
West Virginia (4)
Wisconsin (91)
There are 857,576 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Government
Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform
In a livestreamed meeting Tuesday afternoon, Health Secretary Robert F. Kennedy Jr. drew a dark portrait of the state of America’s health while addressing the MAHA Commission’s most recent report, which includes plans to research potential links between vaccines and rising rates of chronic disease.
September 9, 2025
·
3 min read
·
Heather McKenzie
Press Releases
CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma
September 9, 2025
·
1 min read
Press Releases
Hemostemix Launches Enhanced HubSpot-Powered Websites to Support Global Marketing & Sales of ACP-01 for No-Option Patients
September 9, 2025
·
1 min read
Press Releases
Hemostemix Announces Private Placement
September 9, 2025
·
1 min read
Mergers & Acquisitions
Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises
Executives at Novartis have not been shy about a desire to buy more companies, with cardiovascular a big focus. In total, the Swiss pharma has put $17.23 billion on the line in M&A and licensing deals this year.
September 9, 2025
·
2 min read
·
Annalee Armstrong
Complete response letters
FDA Turns Away Ultra-Rare Disease Therapy
After receiving a complete response letter for its pyruvate dehydrogenase complex deficiency candidate, Saol Therapeutics anticipates it will need “several years” and “significant financial resources” to address the FDA’s concerns.
September 9, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC
Truist Securities called pumitamig’s data on Monday “very reassuring,” given the consistency between its performance in Chinese and global patient populations.
September 9, 2025
·
2 min read
·
Tristan Manalac
IPO
Neuroscience Biotech LB Files for $228M IPO To Support Phase III Plans
If LB is successful, the debut would mark the first IPO in months for the sector, as the biotech industry continues to endure a nuclear winter.
September 9, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Deals in Cardio Again, Dropping $1.4B To Acquire Tourmaline
Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.
September 9, 2025
·
2 min read
·
Tristan Manalac
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
Regeneron’s antibody duos significantly lowered eye itching and redness, as well as pin prick reactivity, in people with cat and birch allergies. Still, BMO Capital Markets expressed uncertainty about the assets’ “commercial potential in a highly generic market.”
September 9, 2025
·
2 min read
·
Tristan Manalac
1 of 85,758
Next
